REGENXBIO Inc. (RGNX) Given Average Recommendation of “Buy” by Analysts
REGENXBIO Inc. (NASDAQ:RGNX) has received an average recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $41.67.
RGNX has been the topic of a number of analyst reports. Chardan Capital upped their price target on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research cut shares of REGENXBIO from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Evercore ISI began coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They set an “outperform” rating and a $25.00 target price on the stock. Finally, BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th.
In other REGENXBIO news, CFO Vittal Vasista sold 3,100 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $18.75, for a total transaction of $58,125.00. Following the transaction, the chief financial officer now owns 107,512 shares in the company, valued at approximately $2,015,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stephen Yoo sold 32,658 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $25.00, for a total transaction of $816,450.00. Following the transaction, the insider now owns 31,803 shares in the company, valued at approximately $795,075. The disclosure for this sale can be found here. Insiders have sold a total of 91,898 shares of company stock worth $2,141,135 in the last 90 days. Company insiders own 17.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc lifted its stake in REGENXBIO by 41.4% during the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 2,011 shares during the period. Oxford Asset Management bought a new position in REGENXBIO during the 1st quarter valued at about $206,000. American International Group Inc. lifted its stake in REGENXBIO by 7.1% during the 1st quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock valued at $241,000 after acquiring an additional 822 shares during the period. Voya Investment Management LLC bought a new position in REGENXBIO during the 2nd quarter valued at about $249,000. Finally, Acadian Asset Management LLC bought a new position in REGENXBIO during the 1st quarter valued at about $272,000. Institutional investors and hedge funds own 73.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “REGENXBIO Inc. (RGNX) Given Average Recommendation of “Buy” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/10/regenxbio-inc-rgnx-given-average-recommendation-of-buy-by-analysts.html.
Shares of REGENXBIO (NASDAQ RGNX) opened at 25.70 on Friday. REGENXBIO has a one year low of $12.82 and a one year high of $25.85. The stock has a 50 day moving average of $20.66 and a 200 day moving average of $19.84. The stock’s market cap is $793.98 million.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.34. The company had revenue of $6.56 million for the quarter. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. On average, analysts forecast that REGENXBIO will post ($2.87) EPS for the current year.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.